Modality
ASO
MOA
IL-13i
Target
SOS1
Pathway
Amyloid
CMLSchizophreniaPTSD
Development Pipeline
Preclinical
~Jun 2010
→ ~Sep 2011
Phase 1
~Dec 2011
→ ~Mar 2013
Phase 2
~Jun 2013
→ ~Sep 2014
Phase 3
~Dec 2014
→ ~Mar 2016
NDA/BLA
~Jun 2016
→ ~Sep 2017
Approved
Dec 2017
→ Feb 2031
ApprovedCurrent
NCT06038755
52 pts·CML
2024-12→2027-05·Not yet recruiting
NCT04123219
2,908 pts·CML
2017-12→2030-05·Recruiting
NCT07759680
2,889 pts·Schizophrenia
2018-01→2031-02·Active
5,849 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2027-05-081.1y awayPh3 Readout· CML
2030-05-284.2y awayPh3 Readout· CML
2031-02-224.9y awayPh3 Readout· Schizophrenia
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Approved
Recruit…
Approved
Active
Approved
Not yet…
Catalysts
Ph3 Readout
2027-05-08 · 1.1y away
CML
Ph3 Readout
2030-05-28 · 4.2y away
CML
Ph3 Readout
2031-02-22 · 4.9y away
Schizophrenia
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06038755 | Approved | CML | Not yet recr... | 52 | DAS28 |
| NCT04123219 | Approved | CML | Recruiting | 2908 | DOR |
| NCT07759680 | Approved | Schizophrenia | Active | 2889 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |